10 U/ml (OR 2.86, p 0.01) remained the only independent factors to predict ovarian cancer recurrence. Conclusions The present paper proposes the validation of a novel CA125 algorithm aiming to detect recurrent EOC. These data may allow us to investigate novel ways of follow up that do not require a patient's physical attendance at a clinic (virtual follow-up)."/>
Skip to main content

Table 3 Multivariate Cox proportional hazards model predicting recurrence

From: The value of serum CA125 for the development of virtual follow-up strategies for patients with epithelial ovarian cancer: a retrospective study

Variables

HR

95% CI

 

P

CA125 doubling

5.10

1.11

23.43

0.036

FIGO stages 3 or 4 vs stage 1 or 2

1.52

0.28

8.30

0.629

Nadir CA125 levels > 10 U/ml

2.86

1.29

6.37

0.010

Residual disease (any vs. nil)

1.06

0.48

2.33

0.893

Cell type (serous vs. other)

1.52

0.55

4.15

0.417